Introduction {#s0005}
============

Bone is one of the most frequent metastatic sites in non-small cell lung cancer (NSCLC) \[[@bb0005]\]. Approximately 30 to 40% of NSCLC patients develop bone metastasis during the course of disease \[[@bb0010]\]. The current treatment options for NSCLC with bone metastases include surgery, radiotherapy, and chemotherapy \[[@bb0015]\]. In addition to these treatments, bone-modifying agents such as zoledronic acid and denosumab (anti-receptor activator of nuclear factor-kappa B ligand antibody) are frequently used to prevent skeletal-related events (SREs) \[[@bb0020]\]. However, prognosis is still poor and median survival time is less than one year after the occurrence of bone metastases in NSCLC patients \[[@bb0010]\].

Metastatic NSCLC frequently involves epidermal growth-factor receptor (EGFR) gene mutation which determines the efficacy of EGFR tyrosine-kinase inhibitors (EGFR-TKIs) \[[@bb0025]\]. Pre-clinical studies have shown that EGFR-TKI and vascular endothelial growth-factor (VEGF) inhibitors work synergistically on tumors with EGFR mutations \[[@bb0030]\]. Erlotinib, a first-generation reversible EGFR-TKI, has been used for advanced EGFR mutation-positive NSCLC patients in combination with bevacizumab (BV), a monoclonal antibody against VEGF \[[@bb0035]\]. Recently osimertinib, a third-generation irreversible EGFR-TKI, has been used for advanced EGFR mutation-positive NSCLC patients as monotherapy \[[@bb0040]\]. However the efficacy of the osimertinib and BV combination for NSCLC patients is still poorly understood \[[@bb0045]\]. In addition, osimertinib, either with or without BV, for bone-metastatic EGFR-mutated NSCLC has not been studied.

In the present study, we established an imageable orthotopic xenograft mouse model of H1975, an EGFR-mutated and T790M-positive NSCLC cell line, expressing red fluorescent protein (H1975-RFP) growing in the mouse tibia and determined the efficacy of osimertinib and osimertinib combined with BV.

Materials and methods {#s0010}
=====================

Cell line and cell culture {#s0015}
--------------------------

The H1975-RFP human EGFR-mutant NSCLC cell line with stable high-expression RFP (AntiCancer, Inc., San Diego, CA) was maintained in RPMI-1640 (Mediatech, Inc. Manassas, VA) with 10% fetal bovine serum. All media were supplemented with penicillin and streptomycin. Cells were cultured at 37 °C with 95% air and 5% CO~2~.

Mice {#s0020}
----

Athymic nu/nu nude mice (AntiCancer, Inc.) were used. The mouse investigations in the present report were carried out using an AntiCancer, Inc. Institutional Animal Care and Use Committee (IACUC) protocol specifically approved for this study as previously described and as per as the principles and procedures provided in the National Institutes of Health Guide for the Care and Use of Animals under Assurance Number A3873-1 \[[@bb0050],[@bb0055]\]. To minimize any suffering of the animals, anesthesia and analgesics were used for all surgical experiments \[[@bb0050],[@bb0055]\]. The mice were observed on a daily basis and humanely sacrificed by over-dosed anesthesia if they met the following humane endpoint criteria: severe tumor burden (more than 20 mm in diameter), prostration, significant body weight loss, difficulty breathing, rotational motion and body temperature drop \[[@bb0050],[@bb0055]\].

Establishment of bone injection NSCLC model {#s0025}
-------------------------------------------

H1975-RFP cells growing in culture were washed with phosphate-buffered saline (PBS, Mediatech, Inc., Manassas, VA) and harvested by trypsinization. H1975-RFP cells (1 × 10^6^/PBS 10 μL + Matrigel 10 μL) were injected into the right tibia of nude mice using a 1 mL tuberculin syringe with a 27G1/2 needle ([Fig. 1](#f0005){ref-type="fig"}).Fig. 1Schema of establishment and observation of the non-small-cell lung cancer (NSCLC) bone-metastasis mouse model.Fig. 1

Treatment study design {#s0030}
----------------------

When average tumor area reached 50--100 mm^2^, the mouse models were randomized into 4 groups of 9 mice each: G1, control (corn oil + 10% DMSO, oral gavage, 28 consecutive days); G2, BV (bevacizumab 5 mg/kg, intraperitoneal injection \[i.p.\], twice per week); G3, osimertinib (25 mg/kg/day, oral gavage, 28 consecutive days); G4, osimertinib (25 mg/kg/day, oral gavage, 28 consecutive days) + BV (5 mg/kg, i.p., twice per week). Tumor size and mouse body weight were measured twice a week. Florescence imaging was with the FluorVivo (INDEC BioSystems, CA, [Fig. 1](#f0005){ref-type="fig"}). Data are presented as mean ± standard error of the mean (SEM).

Mice survival {#s0035}
-------------

Administration of all drugs ended 28 days after treatment initiation. The measurements of tumor size and body weight were continued to observe disease-free survival and overall survival after treatment ended. Each of the mice were sacrificed when net weight loss of more than 20%, tumor size reaching over 20 mm, or morbidity was observed in the mice. All observation of mouse survival ended 50 days after treatment ended (78 days after treatment initiation).

Histological analysis {#s0040}
---------------------

Fresh tumor samples were fixed in 10% formalin and embedded in paraffin before sectioning and staining. Tissue sections were deparaffinized in xylene and rehydrated in an ethanol series. Hematoxylin and eosin (HE) staining was performed according to standard protocol.

Statistical analysis {#s0045}
--------------------

All statistical analyses were performed with statistical software EZR (Saitama Medical Center, Jichi Medical University). Fisher\'s exact test was used for two categorical variables. A normal distribution was assessed with the Shapiro-Wilk test. The Bartlett\'s test was used to verify the homogeneity of variances among groups. One-way ANOVA with Tukey HSD for post hoc analysis was used for the parametric test for inter-group comparison. The paired *t*-test was used for the parametric test to compare the means between two related groups. Kruskal-Wallis with Steel-Dwass for post hoc analysis was used as the non-parametric test for inter-group comparison. All p-values were two sided and p-values of 0.05 or less were considered statistically significant.

Results {#s0050}
=======

Efficacy of BV, osimertinib, and osimertinib + BV on H1975-RFP NSCLC growing in the bone {#s0055}
----------------------------------------------------------------------------------------

Osimertinib and osimertinib + BV regressed the NSCLC bone metastasis ([Fig. 2](#f0010){ref-type="fig"}, [Fig. 3](#f0015){ref-type="fig"}). There was no significant difference in the number of the mice with tumor regression between the osimertinib and osimertinib + BV groups (p = 1.00, [Table 1](#t0005){ref-type="table"}) There were significant differences in tumor size at the final treatment day between osimertinib with/without BV and BV alone (p \< 0.001, [Fig. 3](#f0015){ref-type="fig"}) BV alone inhibited tumor growth compared to the control group. The tumors grew rapidly and all of the mice were sacrificed by day 22 in the control group.Fig. 2Fluorescence images of representative red fluorescent protein (RFP)-expressing NSCLC growing in the tibia of nude mice, from each treatment group, at each time point after the onset of treatment.Fig. 2Fig. 3Quantitative efficacy of drugs on the tumor size of RFP-expressing NSCLC growing in the tibia. Line graphs indicate tumor size at each time point after the onset of treatment relative to the initial tumor size for each treatment and control group. N = 9 mice/group. \*\*\* p \< 0.001. Error bars: ± SEM.Fig. 3Table 1Tumor regression at the final treatment day.Table 1Tumor regressionYesNop valueOsimertinib721.00Osimertinib + BV63

Overall and disease-free survival {#s0060}
---------------------------------

All mice except mice in the control group survived the entire treatment period ([Fig. 4](#f0020){ref-type="fig"}A). Median survival time of mice in each group was 17 days in the control group; 50 days in BV-treated group, 78 days in the osimertinib-treated group, and 78 days in osimertinib + BV-treated group ([Fig. 4](#f0020){ref-type="fig"}A). There was no significant difference in overall survival between the osimertinib-treated and osimertinib + BV treated groups (p = 0.32, [Table 2](#t0010){ref-type="table"}). RFP fluorescence was not detectable in 7 mice in the osimertinib-treated group and 6 mice in the osimertinib + BV-treated group ([Table 1](#t0005){ref-type="table"}). Median disease-free survival time after treatment ended was 28 days in each group and there was no significant difference between the groups (p = 0.93, [Table 2](#t0010){ref-type="table"} and [Fig. 4](#f0020){ref-type="fig"}B).Fig. 4(A) Overall survival curve after treatment initiation of each group. (B) Disease-free survival curve after treatment end of each group.Fig. 4Table 2Overall- and disease-free-survival after the treatment ended.Table 2np valueOverall survivalOsimertinib90.324Osimertinib + BV9  Disease-free survivalOsimertinib70.925Osimertinib + BV6

Histology of H1975-RFP growing in the bone {#s0065}
------------------------------------------

[Fig. 5](#f0025){ref-type="fig"} shows the tumor histology of each group. The control tumor mainly comprised viable highly-dense cancer cells with nuclear atypia and mitosis which could be detected in high-power fields (HPF, [Fig. 5](#f0025){ref-type="fig"}A′). Invading cancer cells in the tumor section could be observed in low-power fields (LPF, [Fig. 5](#f0025){ref-type="fig"}A). Tumors treated with BV alone, which were fluorescently detectable at the sacrifice on the final observation day, also comprised highly-dense cancer cells detected, in both HPF ([Fig. 5](#f0025){ref-type="fig"}B′) and LPF ([Fig. 5](#f0025){ref-type="fig"}B). However, the cancer-cell density was lower than that of control detected by LPF ([Fig. 5](#f0025){ref-type="fig"}B) and necrotic cells characterized by swelling and condensed nuclei were detected in HPF ([Fig. 5](#f0025){ref-type="fig"}B′). There were no residual cancer cells detected in mice with osimertinib alone and osimertinib +BV in either LPF or HPF. Bone remodeling after complete response to the treatment was observed ([Fig. 5](#f0025){ref-type="fig"}C, C′ and D, D′).Fig. 5Tumor histology. (A, A′) Control. (B, B′) BV alone. (C, C′) Osimertinib alone. (D, D′) Osimertinib + BV. Scale bars: 100 μm.Fig. 5

Effect of treatment on body weight {#s0070}
----------------------------------

There was a significant difference in mouse body weight between the BV-treated group and osimertinib treated group (p \< 0.001) or osimertinib + BV-treated group (p = 0.01) at the final treatment day (day 28, [Fig. 6](#f0030){ref-type="fig"}A). However, body weight increase in the BV treated group could be due to increased tumor-weight. There was a significant difference in body weight between pre- and post-treatment in the BV-treated group (p \< 0.01). There was no significant difference between the osimertinib with or without BV-treated groups ([Fig. 6](#f0030){ref-type="fig"}B). There were no other observable side effects in any group.Fig. 6Body weight. (A) Line graphs indicate mouse body weight at each time point after the onset of treatment relative to the initial body weight for each treatment and control group. (B) Bar graphs show mouse body weight in each treatment or control group at pre- and post-treatment times. \* p \< 0.05; \*\*\* p \< 0.001. Error bars: ± SEM.Fig. 6

Discussion {#s0075}
==========

NSCLC is the third-most common cause of bone metastases, following breast and prostate cancer \[[@bb0010]\]. Bone-modifying agents are frequently used as palliative treatment for preventing pathological fracture. However, the use of chemotherapy drugs on bone metastatic NSCLC is still controversial \[[@bb0060]\]. In the present study, the efficacy of osimertinib alone and osimertinib combined with BV for NSCLC bone metastasis was evaluated in model of RFP-labeled EGFR-mutant NSCLC growing in the bone of nude mice.

Osimertinib is now used for the treatment of advanced EGFR-mutant NSCLC patients who have a good performance status \[[@bb0040],[@bb0065]\]. We previously demonstrated the efficacy of osimertinib for brain metastasis of NSCLC using a GFP-labeled NSCLC brain-implant nude-mouse model \[[@bb0070]\]. However, the efficacy of osimertinib on bone metastasis of NSCLC has not been previously investigated. In the present study, we determined that osimertinib could regress EGFR-mutant NSCLC tumors growing in the bone and remodel the bone.

VEGF is overexpressed and circulating levels of VEGF are elevated in lung cancer \[[@bb0075]\], BV has been used for lung cancer treatment in combination with chemotherapy \[[@bb0035]\]. VEGF inhibition enhances the efficacy of EGFR-TKI in EGFR-mutated NSCLC cancer cells \[[@bb0080]\]. BV plus first-generation EGFR-TKI, erlotinib have been used for EGFR-positive advanced NSCLC patients with limited efficacy \[[@bb0035],[@bb0085]\]. Clinical trials for the combination of BV and third-generation EFGR-TKI, osimertinib on EGFR-mutant lung cancers are now undergoing \[[@bb0090]\]. However, the efficacy of this combination for bone metastasis of NSCLC has not been investigated. In the present study, we were not able to demonstrate the advantage of the osimertinib plus BV combination, compared to osimertinib alone, because osimertinib alone regressed the bone metastasis. However, the overall survival of osimertinib +BV treated group tended to be longer than osimertinib alone, but there was not a significant difference. Growth inhibition of this rapid-growing bone tumor model by BV alone compared to control may also suggest the usefulness of adding BV to osimertinib for EGFR-mutated NSCLC bone- metastasis treatment. Future studies will include orthotopic implantation of both NSCLC cell lines and patient tumors in the lung that spontaneously metastasize to the bone \[[@bb0095]\].

In the present study, we implanted RFP-labeled EGFR-mutant NSCLC tumors orthotopically to the mouse bone to track the intraosseous tumors in real time and evaluate drug efficacy. The tumor regression and bone remodeling caused by osimertinib with or without BV suggests this treatment has potential to achieve efficacy against NSCLC bone metastasis in the clinic.
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